Transporting therapeutics across the blood-brain barrier

https://doi.org/10.1016/1357-4310(96)88720-XGet rights and content

In 1996, we are half-way through the Decade of the Brain, yet we still have few effective treatments for major disorders of the central nervous system. These include affective disorders, epilepsy, neurodegenerative disorders, brain tumours, infections and HIV encephalopathy; sufferers far outnumber the morbidity of cancer or heart disease. Increased understanding of the pharmacology of the brain and its blood supply, and methods for rational drug design, are leading to potential new drug therapies based on highly specific actions on particular target sites, such as neurotransmitter receptors and uptake systems. These methods are capable of reducing the side effects that are common with more general treatments. However, all these treatments and potential treatments meet a formidable obstacle—the blood—brain barrier. In this article, we review the properties of this barrier that complicate drug delivery to the brain, and some of the most hopeful strategies for overcoming or bypassing the barrier in humans.

References (41)

  • GreigN.H.

    Drug entry into the brain and its pharmacological manipulation

  • SeeligA. et al.

    A method to determine the ability of drugs to diffuse through the blood—brain barrier

  • GreigN.H.

    Drug delivery to the brain by blood—brain barrier: circumvention and drug modification

  • LambertD.M.

    Synthesis and pharmacological properties of 2-[S-acetylthiorphan]-1,3-diacylaminopropan-2-ol derivatives as chimeric lipid drug carriers containing an enkephalinase inhibitor

    Pharm. Res.

    (1994)
  • van BreeJ.B.M.M.

    Stereoselective transport of baclofen across the blood—brain barrier in rats as determined by the unit impulse response methodology

    Pharm. Res.

    (1991)
  • TakadaY.

    Rapid high-affinity transport of a chemotherapeutic amino acid across the blood—brain barrier

    Cancer Res.

    (1992)
  • RapoportS.I.

    Drug delivery to the brain: barrier modification and drug modification methodologies

    NIDA Res. Monogr.

    (1992)
  • BegleyD.J.

    Peptides and the blood—brain barrier

  • WongS.L. et al.

    Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis

    J. Pharmacol. Exp. Ther.

    (1993)
  • DykstraK.H.

    Microdialysis study of zidovudine (AZT) transport in rat brain

    J. Pharmacol. Exp. Ther.

    (1993)
  • Cited by (415)

    • Novel cell delivery systems: Intracranial and intrathecal

      2022, NK Cells in Cancer Immunotherapy: Successes and Challenges
    • Challenges in targeting to brain and brain tumors

      2022, Nanocarriers for Drug-Targeting Brain Tumors
    • Potential applications of nanomedicine for treating Parkinson's disease

      2021, Journal of Drug Delivery Science and Technology
      Citation Excerpt :

      As the blood-brain barrier consists of low-density lipoprotein receptors, the NP-apolipoprotein complex interacts with these receptors and is internalized by the mechanism of receptor-mediated endocytosis [112]. The delivery of neurotherapeutics to the brain had been a challenge for researchers until the discovery of intranasal drug delivery [113]. This route of drug delivery gained broad attention from researchers due to its various benefits such as overcoming the blood-brain barrier, bypassing hepatic first-pass metabolism, non-invasiveness, convenience of administration, safety, and practicality [114].

    • Interfacing Graphene-Based Materials With Neural Cells/ Brain Transplants for Neuronal Applications in Health Care

      2024, Graphene-Based Nanomaterials: Applications in Food, Agriculture and Healthcare
    View all citing articles on Scopus
    View full text